Navigation Links
Cephalon Signs Option Agreement to Acquire Ception Therapeutics
Date:1/13/2009

Promising Monoclonal Antibody In Late- Stage Clinical Trial for the Treatment of Pediatric Eosinophilic Esophagitis

FRAZER, Pa. and MALVERN, Pa., Jan. 13 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) and Ception Therapeutics, Inc., a privately held biopharmaceutical company, today announced that the companies have signed an agreement providing Cephalon with an option to purchase all outstanding capital stock of Ception. Under the terms of the option agreement, Cephalon will pay Ception a $100 million upfront option payment.

Ception's lead product is reslizumab. Reslizumab is a humanized monoclonal antibody (mAb) against interleukin-5 (IL-5) currently in a Phase IIb/III clinical trial for the treatment of pediatric eosinophilic esophagitis (EE) and in a Phase II clinical trial for the treatment of eosinophilic asthma in adults. Ception also has an established program to discover small molecule, orally-active, anti-TNF (tumor necrosis factor) receptor agents.

Cephalon may exercise its option at any time prior to expiration of a specified period after receipt of the final study report for the pediatric EE clinical trial. If Cephalon exercises its option, the company will purchase all of the outstanding capital stock of Ception for $250 million. Ception shareholders could receive additional payments related to clinical and regulatory milestones.

"This deal builds on our heritage as a biotech company and creates the opportunity for Cephalon to introduce its first biologic into the market," said Frank Baldino, Jr., Ph.D. chairman and CEO of Cephalon. "The addition of biologics, which have a longer commercial life, will add higher value products to our portfolio. Strategically the agreement aligns with our development of prod
'/>"/>

SOURCE Cephalon, Inc.; Ception Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkins Lymphoma
3. Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkins Lymphoma
4. Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain
5. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
6. StatSure Signs Strategic Financing and License Deals with Inverness Medical Innovations
7. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
8. New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings
9. New AVEENO(R) Eczema Care Product Line Offers Breakthrough Formulas to Help Manage the Signs and Symptoms of Eczema
10. ALS Therapy Development Institute Signs Collaboration Agreement with the Allen Institute for Brain Science
11. Rosetta Genomics Signs Agreement With West Coast CLIA Certified Lab to Develop and Validate Tests Applying Companys MicroRNA Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... , May 24, 2013  Auxilium Pharmaceuticals, Inc. (Nasdaq: ... will participate in the Deutsche Bank Health Care Conference ... Waterfront Hotel.  Mr. Adrian Adams , ... an overview of the Company and its product pipeline ...   (Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO ) ...
(Date:5/23/2013)... 3SBio Inc. (NASDAQ: SSRX ... China -based biotechnology company focused on ... today that, at an extraordinary general meeting held ... favor of the proposal to authorize and approve ... dated February 8, 2013, among Decade Sunshine Limited, ...
(Date:5/23/2013)... , May 23, 2013  Haemonetics Corporation (NYSE: ... , CFO & EVP-Business Development, will present at The Deutsche ... Boston, MA on May 29, 2013 ... ) The public may access Mr. Lindop,s ... About Haemonetics Haemonetics (NYSE: HAE ...
Breaking Medicine Technology:Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 2Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 3Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 43SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 3
... * Statistically significant reduction in sedation during ... * Statistically significant reduction in nausea in ... Cambridge, UK, 8th June 2007 - CeNeS ... company, announces,additional data from post-hoc analysis of ...
... Ala.--(BUSINESS WIRE)--Jun 8, 2007 - ProEthic,Pharmaceuticals, Inc., ... develops, licenses, and markets niche,prescription products, today ... the Company's product candidate for the treatment,of ... two poster,presentations at the American Headache Society's ...
Cached Medicine Technology:Further Statistical Analysis of the Recent Phase III trial on Lead,Product M6G Shows Additional Benefits 2Further Statistical Analysis of the Recent Phase III trial on Lead,Product M6G Shows Additional Benefits 3Further Statistical Analysis of the Recent Phase III trial on Lead,Product M6G Shows Additional Benefits 4Further Statistical Analysis of the Recent Phase III trial on Lead,Product M6G Shows Additional Benefits 5Further Statistical Analysis of the Recent Phase III trial on Lead,Product M6G Shows Additional Benefits 6Further Statistical Analysis of the Recent Phase III trial on Lead,Product M6G Shows Additional Benefits 7ProEthic Pharmaceuticals Presents Positive Data for PRO-513 at,American Headache Society Meeting 2ProEthic Pharmaceuticals Presents Positive Data for PRO-513 at,American Headache Society Meeting 3ProEthic Pharmaceuticals Presents Positive Data for PRO-513 at,American Headache Society Meeting 4
(Date:5/24/2013)... Part guidebook, part memoir, Peter Amato, M.A., ... true approach to meditation for the recovery community. Entitled ... Step, the book outlines a comprehensive method for recovering ... step in any 12-step recovery programs such as Alcoholics ... ever-growing global health problem affecting the physical and psychological ...
(Date:5/24/2013)... 2013 ShopPharmacyCounter.com PhenObestin 37.5 Summer Sale ... announced price reductions on their popular PhenObestin 37.5 non-prescription ... clients to lose weight as effortlessly as possible has ... more than 50%. , Bottles have been reduced from ... all orders will receive free shipping. , Made ...
(Date:5/24/2013)... Range Kleen Mfg. strives to “TCOTC.” Our ... from the President's desk to the Shipping Dock.” We hold ... and having passion while creating excellence and quality being results ... to do the right thing and what better way to ... by devastation. , Throughout the year Range Kleen donates to ...
(Date:5/24/2013)... May 24, 2013 Before you start the grill, ... coffee with Kathie Lee Gifford and Hoda Kotb on the Today ... show cool tech ideas to Kathie Lee and Hoda, including the ... our brave men and women in the military who made the ... the BBQ, spend time with friends and family and enjoy the ...
(Date:5/24/2013)... New York, New York (PRWEB) May 24, 2013 ... from the 2010 DePuy hip recall continue to move ... reports. According to documents filed in California’s San ... had been seeking an expedited trial of her DePuy ... (Tilman v. DePuy Orthopaedics, Inc., et al., No. ...
Breaking Medicine News(10 mins):Health News:Guidebook for Recovery Published by Meditation Master Peter Amato 2Health News:Guidebook for Recovery Published by Meditation Master Peter Amato 3Health News:ShopPharmacyCounter.com PhenObestin 37.5 Summer Sale Now On 2Health News:Range Kleen Partners with Berndes in Red Cross Promotion: Taking Care of Oklahoma 2Health News:LawnBott® Visits the Today Show with Kathie Lee and Hoda 2Health News:DePuy ASR Hip Lawsuit News: Bernstein Liebhard LLP Notes Request for Voluntary Dismissal in California DePuy Hip Recall Case 2Health News:DePuy ASR Hip Lawsuit News: Bernstein Liebhard LLP Notes Request for Voluntary Dismissal in California DePuy Hip Recall Case 3Health News:DePuy ASR Hip Lawsuit News: Bernstein Liebhard LLP Notes Request for Voluntary Dismissal in California DePuy Hip Recall Case 4
... country's greenest and cleanest city was not enough, Chandigarh is all ... become the first smoke-free city in the country. ... free by July 1. ,The joint capital of Punjab ... and buildings to ensure that smoking is restricted and the general ...
... a million less AIDS patients than has been widely believed, ... were reported here. ,The survey that was ... out under international supervision shows that India probably no longer ... the New York Times said Friday. ,An official ...
... epilepsy in developing countries are being denied an effective ... according to an editorial in this weeks BMJ. ... in developing countries to ensure that effective treatment is ... people with epilepsy who live in developing countries, around ...
... (hESC), those very young cells that are a biological blank ... to the workings of a wide variety of organs and ... slow to be realized because of the ongoing ethical debate ... its a politically charged issue in the U.S. because it ...
... of tumors and the response of tumors to radiation ... in turn limits oxygen delivery to the tumor, causing ... shown to trigger tumor resistance to radiation via the ... known as HIF-1regulated cytokines. In a study appearing online ...
... community hospita,l in Detroit with 285 beds, specializing in general ... failure, diabetes and obstetrics. ,Detroit is the largest ... a prosperous region. ,But Riverview is all ... week said it was losing too much money and already ...
Cached Medicine News:Health News:Chandigarh to Become India's First Smoke-free City 2Health News:India Has a Million Less AIDS Cases Than Believed: Study 2Health News:Dartmouth Professor Makes Case for Ethically Universal Stem Cell Lines 2Health News:Hospitals in Older Cities Close Down, Blacks Worst Affected 2Health News:Hospitals in Older Cities Close Down, Blacks Worst Affected 3
Intended for the quantitative determination of uric acid in serum or plasma. Reaction: endpoint. Wavelength: 520 nm. Linearity: 20 mg/dL (1190 mol/L). Single vial, dry powder reagent....
The Mikro 20 line of centrifuges has 4 models for microlitre applications complete with rotor. Whether cryo, PCR or standard micro tubes, it is the appropriate centrifuge of choice with angle rotor....
... Engineered for small and medium volume laboratories, ... 1010 System offers the speed, simplicity and ... requirements. Compact yet powerful, the Elecsys 1010 ... rapid response assays to routine testing without ...
The Dimension RxL Max is an integrated chemistry system and is the most powerful and technologically advanced Dimension analyze with new standard for excellence in clinical diagnostics. Simply put, t...
Medicine Products: